RxDoctor Payments Data

Sankararao Tamtam, MD

Internal Medicine · Seguin, TXNPI 1588625735

Payments from drug & device makers

$971in general payments, 2019–2025

Across 46 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$147
  • Mannkind Corporation$131
  • Astellas Pharma US Inc$116
  • Abbott$95
  • Novartis$84
  • Otsuka America Pharmaceutical, Inc.$56
  • plus $343 from 12 others

What the payments were for

  • Food & beverage$81284%
  • Education$10010%
  • Gifts$596%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$971 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$116,851
Medicare patients
539
Services billed
1,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$136,439
EliquisApixaban103$94,692
FarxigaDapagliflozin Propanediol67$51,145
JardianceEmpagliflozin41$43,365
XareltoRivaroxaban38$37,774
Tresiba Flextouch U-200Insulin Degludec33$27,700
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,395
MounjaroTirzepatide17$18,303
EntrestoSacubitril/Valsartan18$12,179
JanuviaSitagliptin Phosphate12$11,987
LinzessLinaclotide19$10,721
Tresiba Flextouch U-100Insulin Degludec14$7,844
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,692
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,687
Atorvastatin Calcium593$5,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$32$136,439127 claims
PfizerEliquis$44$94,692103 claims
AstraZenecaFarxiga, Symbicort$14$54,39079 claims
Johnson & JohnsonXarelto$19$37,77438 claims
GSKTrelegy Ellipta$18$26,39531 claims
Lilly USA, LLCMounjaro$147$18,30317 claims
AbbVieLinzess, Synthroid$52$12,19054 claims
NovartisEntresto$84$12,17918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →